Shenzhiling Oral Liquid Protects STZ-Injured Oligodendrocyte through PI3KAkt-mTOR Pathway
Joint Authors
Wang, Pengwen
Mana, Lulu
Wang, Yahan
Liu, Zhenhong
Qin, Gaofeng
Huang, Shuaiyang
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-07-24
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
White matter degeneration and demyelination are nonnegligible pathological manifestations of Alzheimer’s disease (AD).
The damage of myelin sheath consisting of oligodendrocytes is the basis of AD’s unique early lesions.
Shenzhiling oral liquid (SZL) was the effective Chinese herbal compound approved by the Food and Drug Administration (FDA) for the treatment of AD in China, which plays the exact therapeutic role in clinical AD patients.
However, its molecular mechanism remains unclear to date.
For this purpose, an in vitro mode of streptozotocin- (STZ-) induced rat oligodendrocyte OLN-93 cell injury was established to mimic the pathological changes of myelin sheath of AD and investigate the mechanism of SZL protecting injured OLN-93 cell.
The results showed that STZ can decrease cell viability and downregulate the activity of PI3K/Akt-mTOR signalling pathway and the expression of myelin sheath-related proteins (MBP, MOG, and PLP) in OLN-93 cells.
Both SZL-medicated serum and donepezil (positive control) can protect cells from STZ-caused damage.
SZL-medicated serum increased OLN-93 cell viability in a dose- and time-dependent manner and enhanced the activity of PI3K/Akt-mTOR signalling pathway.
The inhibitor of PI3K (LY294002) inhibited the protective effect of SZL-medicated serum on the STZ-injured OLN-93 cells.
Furthermore, rapamycin, the inhibitor of mTOR, inhibited the promotion of cell viability and upregulation of p-mTOR and MBP caused by SZL-medicated serum.
In conclusion, our data indicate that SZL plays its therapeutic role on AD by promoting PI3K/Akt-mTOR signalling pathway of oligodendrocytes.
Thus, the present study may facilitate the therapeutic research of AD.
American Psychological Association (APA)
Liu, Zhenhong& Qin, Gaofeng& Mana, Lulu& Huang, Shuaiyang& Wang, Yahan& Wang, Pengwen. 2020. Shenzhiling Oral Liquid Protects STZ-Injured Oligodendrocyte through PI3KAkt-mTOR Pathway. Evidence-Based Complementary and Alternative Medicine،Vol. 2020, no. 2020, pp.1-13.
https://search.emarefa.net/detail/BIM-1156176
Modern Language Association (MLA)
Liu, Zhenhong…[et al.]. Shenzhiling Oral Liquid Protects STZ-Injured Oligodendrocyte through PI3KAkt-mTOR Pathway. Evidence-Based Complementary and Alternative Medicine No. 2020 (2020), pp.1-13.
https://search.emarefa.net/detail/BIM-1156176
American Medical Association (AMA)
Liu, Zhenhong& Qin, Gaofeng& Mana, Lulu& Huang, Shuaiyang& Wang, Yahan& Wang, Pengwen. Shenzhiling Oral Liquid Protects STZ-Injured Oligodendrocyte through PI3KAkt-mTOR Pathway. Evidence-Based Complementary and Alternative Medicine. 2020. Vol. 2020, no. 2020, pp.1-13.
https://search.emarefa.net/detail/BIM-1156176
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1156176